MXPA00003972A - Terapia de progestina con sangrado controlado. - Google Patents

Terapia de progestina con sangrado controlado.

Info

Publication number
MXPA00003972A
MXPA00003972A MXPA00003972A MXPA00003972A MXPA00003972A MX PA00003972 A MXPA00003972 A MX PA00003972A MX PA00003972 A MXPA00003972 A MX PA00003972A MX PA00003972 A MXPA00003972 A MX PA00003972A MX PA00003972 A MXPA00003972 A MX PA00003972A
Authority
MX
Mexico
Prior art keywords
progestin
water
present
teaches
progestin therapy
Prior art date
Application number
MXPA00003972A
Other languages
English (en)
Spanish (es)
Inventor
Howard J Levine
Original Assignee
Columbia Lab Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia Lab Bermuda Ltd filed Critical Columbia Lab Bermuda Ltd
Publication of MXPA00003972A publication Critical patent/MXPA00003972A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
MXPA00003972A 1997-10-21 1998-10-21 Terapia de progestina con sangrado controlado. MXPA00003972A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6348597P 1997-10-21 1997-10-21
US09/170,326 US6306914B1 (en) 1997-10-21 1998-10-13 Progestin therapy for maintaining amenorrhea
PCT/US1998/022169 WO1999020282A1 (en) 1997-10-21 1998-10-21 Progestin therapy with controlled bleeding

Publications (1)

Publication Number Publication Date
MXPA00003972A true MXPA00003972A (es) 2004-04-21

Family

ID=26743461

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA00003972A MXPA00003972A (es) 1997-10-21 1998-10-21 Terapia de progestina con sangrado controlado.

Country Status (19)

Country Link
US (3) US6306914B1 (enExample)
EP (1) EP1032399A1 (enExample)
JP (1) JP2003535015A (enExample)
KR (1) KR100581308B1 (enExample)
CN (1) CN1147301C (enExample)
AR (1) AR013981A1 (enExample)
AU (1) AU742166C (enExample)
BR (1) BR9813262A (enExample)
CA (2) CA2307615A1 (enExample)
HU (1) HUP0004133A3 (enExample)
IL (1) IL135742A (enExample)
MX (1) MXPA00003972A (enExample)
MY (1) MY121743A (enExample)
NO (1) NO326856B1 (enExample)
NZ (1) NZ504066A (enExample)
PE (1) PE121799A1 (enExample)
RO (1) RO121319B1 (enExample)
RU (2) RU2261099C2 (enExample)
WO (1) WO1999020282A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
US20040191276A1 (en) * 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
ES2561491T3 (es) * 2001-12-05 2016-02-26 Teva Women's Health, Inc. Anticonceptivos orales para prevenir el embarazo
CA2496618A1 (en) * 2002-05-23 2003-12-04 Michael Holick Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
AU2003297534A1 (en) * 2002-12-24 2004-07-22 Ovion, Inc. Contraceptive device and delivery system
CA2524474A1 (en) * 2003-05-02 2004-11-18 Duramed Pharmaceuticals, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
SI1635843T1 (sl) * 2003-06-25 2009-06-30 Bayer Schering Pharma Ag Terapija, ki vsebuje dienogest, za hormonsko nadomestitev in depresijo
JP2007534622A (ja) * 2003-07-16 2007-11-29 デュラメド ファーマシューティカルズ インコーポレーティッド 連続的エストロゲン投与での避妊薬療法を利用するホルモン処置の方法
EP1761231A1 (en) * 2004-06-07 2007-03-14 Duramed Pharmaceuticals, Inc. Dispenser for progestin used for acute and maintenance treatment of dub
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
JP2009521533A (ja) * 2005-12-27 2009-06-04 デュラメド ファーマシューティカルズ インコーポレーティッド 結合型エストロゲン組成物、アプリケーター、キット、ならびにそれらの作製および使用の方法
CA2637608A1 (en) * 2006-01-20 2007-07-26 Pear Tree Pharmaceuticals, Inc. Method of treating atrophic vaginitis
US8235047B2 (en) 2006-03-30 2012-08-07 Conceptus, Inc. Methods and devices for deployment into a lumen
CA2654152A1 (en) * 2006-06-02 2007-12-13 Pear Tree Women's Health Care Method of treating atrophic vaginitis
GB0616444D0 (en) * 2006-08-18 2006-09-27 Reckitt Benckiser Nv Detergent composition
WO2008091592A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
MX337634B (es) 2008-02-04 2016-03-14 Teva Womens Health Inc Anillos intravaginales monoliticos que comprenden progesterona y metodos de manufactura y uso de los mismos.
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
RU2697369C1 (ru) * 2018-12-21 2019-08-13 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Способ дифференциальной диагностики функциональной гипоталамической аменореи на фоне стресса и энергетического дефицита
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN113288865B (zh) * 2021-06-28 2022-03-08 浙江仙琚制药股份有限公司 一种黄体酮阴道凝胶剂的制备方法
CN114983929A (zh) * 2022-05-16 2022-09-02 安徽万邦医药科技股份有限公司 一种稳定的黄体酮缓释凝胶及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0501523B1 (en) 1983-11-14 1997-04-09 Columbia Laboratories, Inc. Bioadhesive compositions
USD345211S (en) 1992-04-06 1994-03-15 Columbia Laboratories, Inc. Dispensing vial for feminine hygiene products
US5543150A (en) * 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
USD375352S (en) 1994-03-14 1996-11-05 Columbia Laboratories, Inc. Dispensing vial for feminine hygiene products

Also Published As

Publication number Publication date
KR100581308B1 (ko) 2006-05-22
IL135742A0 (en) 2001-05-20
AR013981A1 (es) 2001-01-31
CA2307615A1 (en) 1999-04-29
MY121743A (en) 2006-02-28
RU2005101612A (ru) 2006-07-10
AU1191499A (en) 1999-05-10
US6306914B1 (en) 2001-10-23
NO326856B1 (no) 2009-03-02
AU742166B2 (en) 2001-12-20
AU742166C (en) 2005-07-14
EP1032399A1 (en) 2000-09-06
PE121799A1 (es) 1999-12-17
BR9813262A (pt) 2000-08-22
US20010031747A1 (en) 2001-10-18
RO121319B1 (ro) 2007-03-30
NZ504066A (en) 2002-11-26
CN1147301C (zh) 2004-04-28
RU2330667C2 (ru) 2008-08-10
WO1999020282A1 (en) 1999-04-29
RU2261099C2 (ru) 2005-09-27
NO20002084L (no) 2000-06-21
JP2003535015A (ja) 2003-11-25
US6593317B1 (en) 2003-07-15
IL135742A (en) 2004-09-27
KR20010031299A (ko) 2001-04-16
HUP0004133A3 (en) 2001-09-28
NO20002084D0 (no) 2000-04-19
HUP0004133A2 (hu) 2001-05-28
CA2649671A1 (en) 1999-04-29
CN1282250A (zh) 2001-01-31

Similar Documents

Publication Publication Date Title
MXPA00003972A (es) Terapia de progestina con sangrado controlado.
LT96027A (en) Use of a cross-linked polycarboxylic polymer and progesterone for manufacture of medicinal preparations
GR3015116T3 (en) Iontophoretic drug delivery system with two-stage delivery profile.
GEP20063773B (en) Steroid Sulphatase Inhibitors
RU2000112650A (ru) Прогестинотерапия с регулируемым кровотечением
PT100323A (pt) Dispositivo para a reducao das sensacoes durante a administracao iontoforetica de um agente terapeutico
IL115495A0 (en) Use and composition of an anti-sexually transmitted disease formulation
GR3019124T3 (en) Solid matrix system for transdermal drug delivery.
HU9401849D0 (en) Transdermally administrated system containing acetylsalicylic acid for thrombosis therapy and cancer prophylaxis
NZ332894A (en) A regimen containing progestogen and/or estrogen with two or more anti-progestogen dosage units
MX9702162A (es) Procedimiento para hacer unidades de dosis mediante granulacion en humedo.
DE59807891D1 (de) Transdermales therapeutisches system (tts) enthaltend ammoniogruppenhaltige (meth)acrylatpolymere zur verabreichung von levonorgestrel
AU6821687A (en) System for delivering drug with enhanced bioacceptability
ES366313A1 (es) Procedimiento de preparacion de composiciones moldeadas controladoras de la ovulacion del estro en bovinos.
GB9905663D0 (en) Iodine preparation composition
SI0711163T1 (en) Use of benzydamine in the treatment of pathological conditions caused by tnf
GEP20043253B (en) Progestin Therapy with Controlled Bleeding
SM et al. Low dose ketamine infusion for obstetrical delivery
JPS55149212A (en) Gradually releasing preparation of methotrexate
UA95691C2 (ru) Фармацевтическая вагинальная композиция и ее применение

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees